Currently, there are 13.01M common shares owned by the public and among those 7.40M shares have been available to trade.
The company’s stock has a 5-day price change of 4.73% and 3.03% over the past three months. OTLK shares are trading 9.52% year to date (YTD), with the 12-month market performance down to -58.11% lower. It has a 12-month low price of $4.00 and touched a high of $40.60 over the same period. OTLK has an average intraday trading volume of 162.87K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.90%, 8.05%, and -42.31% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Outlook Therapeutics Inc (NASDAQ: OTLK) shares accounts for 11.47% of the company’s 13.01M shares outstanding.
It has a market capitalization of $112.28M and a beta (3y monthly) value of -0.02. The earnings-per-share (ttm) stands at -$3.99. Price movements for the stock have been influenced by the stock’s volatility, which stands at 17.88% over the week and 15.26% over the month.
Analysts forecast that Outlook Therapeutics Inc (OTLK) will achieve an EPS of -$0.85 for the current quarter, -$0.85 for the next quarter and -$2.05 for 2025. The lowest estimate earnings-per-share for the quarter is -$1.2 while analysts give the company a high EPS estimate of -$0.43. Comparatively, EPS for the current quarter was -$0.6 a year ago. Earnings per share for the fiscal year are expected to increase by 28.74%, and 32.11% over the next financial year.
Looking at the support for the OTLK, a number of firms have released research notes about the stock. Chardan Capital Markets stated their Buy rating for the stock in a research note on February 15, 2024, with the firm’s price target at $3. CapitalOne was of a view on December 27, 2023 that the stock is Overweight, while H.C. Wainwright gave the stock Neutral rating on August 31, 2023, issuing a price target of $5- $1. Chardan Capital Markets on their part issued Neutral rating on August 31, 2023.
